Jun 13, 2024, 07:54
Connect to the ESMO Virtual Plenary to stay up to date with the latest in immunotherapy
ESMO shared on LinkedIn:
“What are the early safety and activity profiles of a first-in-class PD-1/IL-2 bispecific in patients with solid tumors?
Connect today to the ESMO Virtual Plenary with international experts in oncology to stay up to date with the latest in immunotherapy.”
Source: ESMO/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 23, 2024, 06:21
Dec 23, 2024, 06:08
Dec 23, 2024, 06:05
Dec 23, 2024, 06:00
Dec 23, 2024, 05:43
Dec 22, 2024, 18:02
Dec 22, 2024, 17:54